Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas

ASCO 2026

29 May - 2 Jun 2026

Published: 30 May 2026

Views: 24

Rating:

Save

Dr Georg Lenz - University Hospital Münster, Münster, Germany

At ASCO 2026, Dr Georg Lenz discusses results from the phase III frontMIND study with ecancer, evaluating tafasitamab plus lenalidomide and R-CHOP in patients with newly diagnosed high-risk diffuse large B-cell lymphoma and high-grade B-cell lymphoma.

The combination significantly improved progression-free survival and event-free survival compared with R-CHOP alone, supporting its potential as a new first-line treatment option for high-risk disease.

Related Videos

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2...

Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results ( Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy )

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant...

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

SIOG 2024: Updates in haematology

Dr Ashley Rosko - The Ohio State University, Columbus, USA

SIOG 2024: Updates in haematology ( Dr Ashley Rosko - The Ohio State University, Columbus, USA )

Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )

Approaches to risk stratification in high risk myeloma

Dr Irene Ghobrial - Dana-Farber Cancer Institute, Boston, USA

Approaches to risk stratification in high risk myeloma ( Dr Irene Ghobrial - Dana-Farber Cancer Institute, Boston, USA )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Status of anti BCMA therapy in myeloma

Dr Dibakar Podder - Tata Medical Center, Kolkata, India

Status of anti BCMA therapy in myeloma ( Dr Dibakar Podder - Tata Medical Center, Kolkata, India )

More from ecancer